132.73
0.12 (0.09%)
| Previous Close | 132.61 |
| Open | 132.72 |
| Volume | 5,377,273 |
| Avg. Volume (3M) | 2,288,203 |
| Market Cap | 9,979,133,952 |
| Price / Book | 7.94 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Apogee Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 4.0 |
| Average | -1.75 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAMBKOWSKI CARL | - | 132.55 | -26,400 | -3,499,320 |
| HENDERSON MICHAEL THOMAS | - | 132.55 | -80,000 | -10,604,000 |
| Aggregate Net Quantity | -106,400 | |||
| Aggregate Net Value ($) | -14,103,320 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 132.55 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | Officer | 22 Jun 2026 | Automatic sell (-) | 80,000 | 132.55 | 10,604,000 |
| DAMBKOWSKI CARL | Officer | 22 Jun 2026 | Automatic sell (-) | 26,400 | 132.55 | 3,499,320 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |